Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tamara Ghanem

- PMLiVE

Fishawack acquires creative consultancy Blue Latitude Health

The Fishawack Group has acquired Blue Latitude Health, based in London, UK, and New York, USA. Blue Latitude Health is a creative consultancy combining the commercial focus of a consultancy...

Avalere Health

- PMLiVE

Business warning as talk of Brexit ‘No deal’ grows

'Managed no deal' plan is 'not a credible position' warns business

- PMLiVE

China first market to approve AZ’s kidney drug roxadustat

A milestone for China and AZ and partners FibroGen

Season’s Greetings

Do you have Tinsilitus?

Cuttsy + Cuttsy

Lucid Winter Meeting 2018

The teams gathered at The Artisan in Clerkenwell, London, to reflect on the year and celebrate both team and individual contributions to Lucid, their clients and the local community through...

Lucid Group Communications Limited

2018 was a magical year for Lucid Group, filled with memorable moments and many celebrations

This year has been a ground-breaking year for Lucid Group, punctuated by magical makeovers, plenty of awards, landmark staff celebrations and worthwhile charity work.The tone of the year was set...

Lucid Group Communications Limited

- PMLiVE

Horizon Discovery and C4X to harness CRISPR for new cancer drugs

UK companies combine computational and genomic platforms

- PMLiVE

D-day: time to make digital deliver

Chris Ross looks at why a platform-based, outcomes-focused approach could be key to demonstrating the value of digital health solutions

- PMLiVE

Biogen files Tecfidera follow-up in the US

Improved GI tolerability is major selling point

- PMLiVE

Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion

- PMLiVE

Roche gains EU PRIME status for Spinraza rival

Oral treatment joins Novartis' gene therapy challenger

- PMLiVE

Ex-Pharmacyclics CEO invests $25m in Summit

After Duchenne drug failure, UK biotech looks to new anti-infective

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links